Understand the source comparison
Peptides Help With IBD: Clinical Mechanism Comparison
BPC-157 VEGFR2 activation, angiogenesis promotion Mucosal repair, ulcer healing Preclinical strong, human limited Subcutaneous or intraperitoneal (oral bioavailability poor) Most promising for structural repair but human dosing protocols unclear KPV (tripeptid
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGFR2 activation, angiogenesis promotion
- Mucosal repair, ulcer healing
- Preclinical strong, human limited
- Subcutaneous or intraperitoneal (oral bioavailability poor)
- Most promising for structural repair but human dosing protocols unclear
- KPV (tripeptide)
- NF-κB inhibition in epithelial cells
- Acute inflammation reduction
- Phase 2 human data available
- Enema or subcutaneous (requires local delivery)
- Best-supported for symptom control in mild-moderate UC
- Thymosin alpha-1
- T-regulatory cell modulation
- Immune tolerance restoration
- Small pilot studies only
- Subcutaneous injection
- Targets root immune dysfunction but lacks large-scale validation
- Thymosin beta-4
- Epithelial migration, wound healing
- Barrier function restoration
- Preclinical models only
- Subcutaneous or IP
- Early-stage research. Mechanism compelling but human data absent